Navigation Links
Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
Date:1/9/2008

SAN DIEGO, Jan. 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive results from a single dose Phase 1a clinical trial of APD791 and the initiation of a multiple dose Phase 1b clinical trial to further evaluate the compound's safety, pharmacokinetics and pharmacodynamics. APD791 is Arena's internally discovered oral drug candidate intended for the treatment of arterial thrombosis.

The Phase 1a trial was a randomized, placebo-controlled, double-blind, single-ascending dose trial in 90 healthy male and female volunteers. Doses originally intended for study ranged from 1 mg to 160 mg, but due to excellent tolerability the maximum dose was increased to 320 mg. Doses were well tolerated, without any dose related adverse events, such that a maximum tolerated dose could not be defined despite achieving high concentrations in blood. APD791 was rapidly absorbed and exposures were generally related to dose. Terminal half-life (t1/2) of the parent plus active metabolites was also related to dose, and was approximately 11 hours at the higher doses. Dose dependent inhibition of serotonin-mediated amplification of platelet aggregation was demonstrated starting at the 1 mg dose, supporting APD791 preclinical data and establishing initial clinical validation of APD791's novel mechanism of action.

Based on the positive Phase 1a results, a Phase 1b trial was initiated. The Phase 1b trial is a randomized, placebo-controlled, double-blind, multiple-ascending dose trial in up to 50 healthy male and female volunteers between the ages of 19 and 45 years old. In addition to evaluating APD791's safety and tolerability profile, the trial will also evaluate the pharmacokinetics and pharmacodynamics of multip
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
4. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
5. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
6. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
7. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
8. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
9. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
10. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
11. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Pa. , Sept. 15, 2014 /PRNewswire-iReach/ -- ... -based biotechnology company developing calcium phosphate (CaP)-based nanoparticle ... the company has entered a License Agreement with ... biotechnology company developing immunotherapy products for the treatment ... Under the terms of the agreement, ...
(Date:9/15/2014)... , Sept. 15, 2014  Over 200 ... one roof Saturday to learn, interact and participate ... York City,s first Lupus Trials Fair launched by ... the S.L.E. Lupus Foundation .  Attendees interacted ... institutions -- sharing experiences, ideas and needs and ...
(Date:9/15/2014)... LINCOLNSHIRE, Ill. , Sept. 15, 2014 /PRNewswire/ ... testing equipment and information systems technology, announced today ... (LABSCO).  This agreement is for Sysmex reagents, controls ... Sysmex pocH-100 i ™ , Sysmex XP-300™, ... The agreement is effective immediately and continues ...
Breaking Medicine Technology:CaPtivate Pharmaceuticals Enters License Agreement With Immunotope 2CaPtivate Pharmaceuticals Enters License Agreement With Immunotope 3Lupus Research Institute Launches NYC's First Lupus Trials Fair 2Lupus Research Institute Launches NYC's First Lupus Trials Fair 3Sysmex America, Inc. Renews LABSCO Distributorship 2Sysmex America, Inc. Renews LABSCO Distributorship 3
... July 14 Samsung Medical Center and the world,s leading bio-pharmaceutical company ... research partnership to jointly analyze tumors from Korean patients to generate gene expression ... patients with liver cancer. , , ... http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) , , , ...
... , SANTA ROSA, Calif. , July 14 ... Santa Rosa, California , today received a notice of ... company which was started in 2006 has thirteen additional patent ... the world for related spinal therapies and devices. The lead ...
Cached Medicine Technology:Pfizer and SMC Collaborate on Liver Cancer 2Pfizer and SMC Collaborate on Liver Cancer 3Osseon Receives Patent Allowance for Novel Spinal VCF Treatment Devices 2
(Date:9/15/2014)... The Best Hospitals Honor Roll ... of seven hospitals using OnBase as their enterprise ... Clinic were ranked at the top of the list, ... cover nearly 5,000 medical centers across the country with ... scored highest in at least six of the sixteen ...
(Date:9/15/2014)... Dotinga HealthDay Reporter , ... cholesterol-lowering drugs are more likely to fill their prescriptions ... generic brands, new research suggests. At issue are ... Crestor, Zocor and Lipitor. Generic statins are also available. ... heart problems due to clogged arteries. About ...
(Date:9/15/2014)... The White House has recently begun shifting ... jail and prison and toward helping them access addiction ... positive change. , The nation is currently grappling with ... to an article from The Washington Post , ... away from using the criminal justice system to address ...
(Date:9/15/2014)... Dennis Thompson ... News) -- The severe respiratory virus believed to have ... states has now spread to the Northeast, health officials ... confirmed on Friday more than a dozen cases of ... for children with asthma. And on Saturday, the ...
(Date:9/15/2014)... Array Health , an independent ... that Independence Blue Cross (Independence), the ... selected the Array Spectrum™ Private Exchange solution for ... employers with more than 100 employees. Using the ... offer employer groups a comprehensive selection of products ...
Breaking Medicine News(10 mins):Health News:Seven of Top Ten Hospitals in the U.S. Leverage OnBase by Hyland ECM Solution 2Health News:Older Patients More Likely to Fill Prescriptions for Generic Statins: Study 2Health News:Older Patients More Likely to Fill Prescriptions for Generic Statins: Study 3Health News:White House Shifts Policy on Drugs 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 3Health News:Independence Blue Cross Selects Array Spectrum™ Private Health Insurance Exchange Technology 2Health News:Independence Blue Cross Selects Array Spectrum™ Private Health Insurance Exchange Technology 3
... to press ahead or wait; job creation is public,s top ... of Americans want some kind of health reform in the ... a good thing if the legislation proposed by the Democrats ... if health reform would be good or bad for the ...
... , , FAIRFIELD, N.J. , Feb. 11 ... without the right footwear. And the actual surface for the ... Athletic™ lineup of portable fitness mats and interlocking gym flooring ... basic stretching, Shock Athletic products offer a broad range of ...
... , ... a lawyer with the Louthian Law Firm in Columbia, S.C., says developments in lawsuits ... cannot seek justice. , ... Columbia, South Carolina (PRWEB) February 11, 2010 -- The anti-smoking patch Chantix continues ...
... ... panic as the long-term shortage of Armour Thyroid, Nature-Throid, and Westhroid continues. The ... is a little-known secret that thousands of Americans have already discovered. There is ... ...
... ... Humber NHS Framework, in addition to two in Dec & Jan, with Acute & Mental ... , ... 11, 2010 -- BigHand, a leading provider of voice technology to the healthcare market, has ...
... , DENVER, CO , Feb. 10 ... ( MIT ) is pleased to announce that its ... the production certification to produce Med-Jet products in China ... subject of a recent visit by the SFDA. These facilities ...
Cached Medicine News:Health News:Poll Shows Eroding Support for Health Reform 2Health News:Poll Shows Eroding Support for Health Reform 3Health News:Poll Shows Eroding Support for Health Reform 4Health News:For a Healthier, Cleaner Fitness Regimen - Venture Products' Shock Athletic(TM) Mats and Interlocking Flooring 2Health News:For a Healthier, Cleaner Fitness Regimen - Venture Products' Shock Athletic(TM) Mats and Interlocking Flooring 3Health News:South Carolina Attorney Says Legal Options Still Available To Those Harmed By Chantix 2Health News:South Carolina Attorney Says Legal Options Still Available To Those Harmed By Chantix 3Health News:No End In Sight To The Armour Thyroid Shortage? 2Health News:No End In Sight To The Armour Thyroid Shortage? 3Health News:Three NHS Trusts Choose BigHand Voice Technology Under YHCPC Framework Agreement 2Health News:Major milestone achieved by our joint venture in China 2Health News:Major milestone achieved by our joint venture in China 3
... SF (slot format) microfiltration units provide a ... acid in solution onto nitrocellulose or Zeta-Probe ... by using interchangeable templates to form the ... Bio-Dot SF apparatus. Each is available as ...
Dot Blotter - 96-Well Dot Blot...
... base with vacuum stage, porous vacuum plate, reservoir ... instructions. The Model 785 vacuum blotter quickly ... agarose gel onto a nylon membrane. Because it ... nucleic acid samples can be separated on a ...
Mini Trans-Blot and PowerPac 300 System, 110-120 V...
Medicine Products: